# US 2020/0390769 A1 · Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390769 A1
- Document ID: US20200390769A1
- Status: Published application
- Kind: A1
- Application number: 16/914,703
- Filed: 2020-06-29
- Published: 2020-12-17
- Earliest claimed: 2017-11-06
- Assignees: Tiziana Life Sciences PLC
- Applicants: Tiziana Life Sciences PLC
- Inventors: Kunwar SHAILUBHAI
- Web page: https://patentgrep.com/patent/US20200390769A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61K 31/47: Quinolines; Isoquinolines
- A61P 35/00: Antineoplastic agents
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This application relates to methods of treating and/or preventing cancer (e.g., non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma) in patients in need thereof comprising administering to the patient a therapeutically effective amount of a CDK inhibitor (e.g., milciclib) in combination with a therapeutically effective amount of another anticancer drug (e.g., sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib).

## Claims

### Claim 1

A method of treating or preventing cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a CDK inhibitor, or a pharmaceutically acceptable salt, isomer, or tautomer thereof, in combination with a therapeutically effective amount of another anticancer drug.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cancer is non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, melanoma, multiple myeloma, mantle cell lymphoma, non-Hodgkin's lymphoma, colorectal cancer, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, skin cancer, ovarian cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma.

### Claim 3 (depends on 1)

The method of claim 1, wherein the CDK inhibitor is milciclib or a pharmaceutically acceptable salt thereof, and the other anticancer drug is sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, palbociclib, afatinib, alectinib, axitinib, bortezomib, bosutinib, cabozantinib, carfilzomib, ceritinib, cobimetinib, crizotinib, dabrafenib, erlotinib, gefitinib, ibrutinib, idelalisib, imatinib, ixazomib, lapatinib, nilotinib, nintedanib, niraparib, osimertinib, pazopanib, pegaptanib, ponatinib, rucaparib, ruxolitinib, sonidegib, tofacitinib, trametinib, vandetanib, vemurafenib, vismodegibor, or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 3)

The method of claim 3, wherein the other anticancer drug is sorafenib or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 4)

The method of claim 4, wherein the therapeutically effective amount of sorafenib is 400 mg twice daily, 200 mg twice daily, or 200 mg once daily.

### Claim 6 (depends on 4)

The method of claim 4, wherein the cancer is renal cell carcinoma or thyroid carcinoma.

### Claim 7 (depends on 3)

The method of claim 3, wherein the other anticancer drug is lenvatinib or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein the therapeutically effective amount of lenvatinib is 8, 10, 12, 14, 18, 20, 22, 24, 26, 28, 30, 32, or 34 mg once daily.

### Claim 9 (depends on 7)

The method of claim 7, wherein the cancer is renal cell carcinoma or thyroid carcinoma.

### Claim 10 (depends on 3)

The method of claim 3, wherein the other anticancer drug is regorafenib or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein the therapeutically effective amount of regorafenib is 80, 100, or 120 mg once daily for three weeks, followed by one week of no administration, wherein the cycle is optionally repeated.

### Claim 12 (depends on 10)

The method of claim 10, wherein the cancer is colorectal cancer or gastrointestinal stromal tumors.

### Claim 13 (depends on 3)

The method of claim 3, wherein the other anticancer drug is sunitinib or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein the therapeutically effective amount of sunitinib is 12.5, 25, 37.5, 50, 62.5, 75, 87.5, or 100 mg once daily continuously or for 4 weeks followed by two weeks of no administration, wherein the cycle is optionally repeated.

### Claim 15 (depends on 13)

The method of claim 13, wherein the cancer is renal cell carcinoma or gastrointestinal stromal tumors.

### Claim 16 (depends on 3)

The method of claim 3, wherein the other anticancer drug is nivolumab.

### Claim 17

(canceled)

### Claim 18 (depends on 3)

The method of claim 3, wherein the other anticancer drug is gemcitabine or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the therapeutically effective amount of gemcitabine is 1000 mg/m2 over 30 minutes once weekly for seven weeks, followed by one week of no administration, wherein the cycle is optionally repeated.

### Claim 20

(canceled)

### Claim 21 (depends on 3)

The method of claim 3, wherein the other anticancer drug is palbociclib or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein the therapeutically effective amount of palbociclib is 75, 100, or 125 mg once daily for 3 weeks followed by one week of no administration, wherein the cycle is optionally repeated.

### Claim 23

(canceled)

### Claim 24 (depends on 3)

The method of claim 3, wherein the therapeutically effective amount of milciclib is 50, 75, 100, 125, or 150 mg once daily for four consecutive days, followed by non-administration for 3 consecutive days, wherein the cycle is optionally repeated.

### Claim at position 25

-52. (canceled)

### Claim 53 (depends on 1)

The method of claim 1, wherein the CDK inhibitor and the other anticancer drug are administered in temporal proximity.

### Claim at position 27

-62. (canceled)
